Ligand Pharmaceuticals Incorporated Harvard Case Solution & Analysis

In the active role of hedge fund Third Point LLC has three board seats and a share of 9.5% in the pharmaceutical ligands, Inc specialty pharmaceutical company. The third point is believed that the ligand was a strong drug portfolio and pipeline, but he was a very underrated because of poor management. After obtaining board representation, the third point is convinced that the other directors to try to sell the company. Six months have passed since the ligand began soliciting applicants, but no buyer was. Upon the sale of the company appear to have stalled, and the third point is to decide whether to restart the bidding process, to keep the long-term position, or leave. "Hide
by Nabil N. El-Hage, Michael Gorzynski Source: Harvard Business School 22 pages. Publication Date: November 27, 2007. Prod. #: 208019-PDF-ENG

Ligand Pharmaceuticals Incorporated Case Solution Other Similar Case Solutions like

Ligand Pharmaceuticals Incorporated

Share This